Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555600 | 0.98 | TSHR (0.44) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL30711 | 0.79 | — | — | |
| SCHEMBL176333 | 0.78 | MEN1 (0.36) | TSHRALDH1A1MEN1POLBKMT2A | |
| SCHEMBL4143916 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4149480 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4154180 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL1627440 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4140372 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL267542 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4148516 | 0.78 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813513-A | Quantum dot surface organic ligand composition and preparation method thereof | 苏州威迈芯材半导体有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| CN-116813513-A | Quantum dot surface organic ligand composition and preparation method thereof | 苏州威迈芯材半导体有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-10351591-B2 | Polypeptides, peptides, and proteins functionalized by alkylation of thioether groups via ring-opening reactions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190169161-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, LENS, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20180105553-A1 | POLYPEPTIDES, PEPTIDES, AND PROTEINS FUNCTIONALIZED BY ALKYLATION OF THIOETHER GROUPS VIA RING-OPENING REACTIONS | NATIONAL SCIENCE FOUNDATION | 2018-04-19 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9023583-B2 | Monolayer or multilayer forming composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20130216956-A1 | MONOLAYER OR MULTILAYER FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
| EP-0634895-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993019599-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | USP2 4813/4885TSHR 914/4885KDM4E 2949/4885 |
| US-20180105553-A1 | POLYPEPTIDES, PEPTIDES, AND PROTEINS FUNCTIONALIZED BY ALKYLATION OF THIOETHER GROUPS VIA RING-OPENING REACTIONS | PTMS, TMT1A, PTMA | USP2 931/4885TSHR 1100/4885KDM4E 2339/4885 |
| US-20190169161-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, LENS, AND COMPOUND | CRYAA, CRYZ, CRYAB | USP2 764/4885TSHR 4227/4885KDM4E 1152/4885 |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | USP2 3359/4885TSHR 3780/4885KDM4E 3087/4885 |
| US-10351591-B2 | Polypeptides, peptides, and proteins functionalized by alkylation of thioether groups via ring-opening reactions | PTMS, TMT1A, PTMA | USP2 931/4885TSHR 1100/4885KDM4E 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.